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Abstract: Lymphatic filariasis is one of the neglected tropical diseases. It is estimated that 120 million people are
currently infected in 73 countries where filariasis is endemic. Lymphatic filariasis is a leading cause of chronic
disability worldwide, including of 15 million people who have lymphoedema (elephantiasis) and 25 million men
who have hydrocoele.
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The Global Programme to Eliminate Lymphatic
Filariasis (GPELF) has been one of the most rapidly
expanding global health programmes in the history of pub-
lic health. The programme was launched in 2000 in
response to resolution WHA50.29, with the goal to elimi-
nate lymphatic filariasis as a public-health problem by
2020 (Fig. 1).
Fig. 1 Global status
The GPELF has two strategic aims: (i) interruption of
transmission, using combinations of two medicines deliv-
ered to entire populations at risk, a strategy known as mass
drug administration (MDA); and (ii) morbidity manage-
ment and disability prevention (MMDP), by providing
access to basic care to every affected person in endemic
areas (Fig. 2.).
The World Health Organization has developed a
GPELF framework and guidelines for Member States to
accelerate their efforts towards elimination of lymphatic
filariasis by 2020 (Fig. 3).
The GPELF strategy for transmission interruption has
two objectives with microfilariacide; the first one is to
reduce the density of the microfilariae in the blood of
infected people to a level at which they can no longer be
Fig. 2 Global elimination programme
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transmitted by mosquito vectors to a new human host, and
the scond one is to reduce the prevalence of microfilariae
in the community to a level at which transmission can no
longer be sustained, even in the presence of mosquito vec-
tors. These two objectives are achieved by mass drug
administration, MDA (Fig. 4).
MDA should cover everybody except children age
below 2, pregnant women and very sick people in the com-
munity at the same time to make the microfilariae free sit-
uation in the community once a year. Then, MDA should
continue for at least 5 years, which is generally considered
to be the reproductive lifespan of an adult worm in an
infected host (Fig. 5).
The technical policies for MDA involve 1) combina-
tion of drugs, 2) single-dose annual treatment for 5 years
and 3) to cover all eligible individuals in the entire
endemic area (Fig. 6).
Fig. 3 Framework
Fig. 4 Why MDA
Of the 73 endemic countries, 53 are implementing
MDA, and 12 have moved to the post-MDA surveillance
phase. During 2000–2012, more than 4.2 billion doses of
medicine were delivered to a cumulative targeted popula-
tion of 979 million people (Fig. 7).
The first decade of GPELF was characterized by
rapid scaling up of mapping and MDA. In addition, nine
out of originally endemic countries at the start of GPELF
were re-classified as non-endemic in 2010. A number of
countries have even successfully moved up to the post-
MDA surveillance stage. Intensified activities in the next
five years will be essential to achieving the global elimina-
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QUESTIONS AND DISCUSSION
Shinjiro Hamano Thank you very much Dr. Ichimori.
Now, we open this for your comment or question to
her. Professor Hirayama?
Kenji Hirayama Very big story about MDA. Somehow
that is one of the models of elimination program and
so that’s why following one, maybe some of the
schisto or malaria. I think the big step from the
PacELF to the global one, what were major difficul-
ties or major challenge to scale up to the global levels,
the medicine or… What was the issue at that time?
Kazuyo Ichimori Thank you very much. The PacELF is
a Pacific program to eliminate lymphatic filariasis, is
a part of the Global Programme. When I was in the
Pacific, I mainly worked with the people for MDA
implementation. After I moved to HQ I was in charge
and looked after the global LF elimination pro-
gramme. The challenge in the global level is—we
have to develop the global policies and international
standard guidelines for everybody in the world. It’s
not only the Pacific areas but also any other areas we
have to cover. Therefore, we should make very clear
and core policies and basic guidelines which can be
used by any countries. That’s what we are trying to
Fig. 7 Progress
do. Maybe, I am not answering to your question,
but…
Kenji Hirayama Yes, country level involvement is
really essential.
Jun Kobayashi Jun Kobayashi. I come from Japan
Consortium for Global School Health Research.
Thank you very much. Always, Dr. Ichimori presen-
tation, we feel very strong passion for eliminations of
filariasis. I have very simple question. I visit several
countries for discussion not only filariasis MDA or
soil-transmitted helminths MDA. When we can stop
MDA? Of course, filariasis MDA is very effective for
short span, but when we are thinking of long span,
only MDA we can eliminate or we can eradicate. This
is sure, because for soil-transmitted helminths, always
we are thinking when we can stop MDA. This is a
question come from each country. But, we have no
clear answer, when we can stop. Maybe, for STH
control, we have to do comprehensive package. They
are effective. But for filariasis, maybe, MDA is effec-
tive I believe. This is a question. Do you have already
evidence from some country what timing or stop
MDA?
Kazuyo Ichimori For LF, as I said the transmission
assessment survey guideline we have. That is kind of
new survey tool or survey method showing how to
stop MDA. We had a lot of research people’s idea and
evidence for a survey method, and, we worked
together to make a standard survey method and WHO
made it as a survey guideline—which is Transmission
Assessment Survey-TAS. Countries can follow the
guidelines. If the countries have more than 5 times
MDA with good coverage as 65%. and if the result of
the sentinel site survey is below 1%, they have to con-
sider the transmission assessment survey. The trans-
mission assessment survey is a decision-making
survey—it is a yes or no survey. If they pass this
transmission assessment survey, they can stop MDA
and then move to the post-MDA surveillance stage. If
fail, they have to continue MDA. We believe that
MDA for LF policy and guidelines including TAS is
very clear.
Jun Kobayashi Thank you very much, but, maybe my
question is not clear. Guideline for when stop MDA
or filariasis come from evidence from simulation or
evidence from some country experience, which one?
Kazuyo Ichimori Yes, all guidelines are based on the
evidence including country’s experiences and
research evidence, also the statisticians or epidemiol-
ogist ideas too. For TAS guideline, the research
groups all over the world including groups supported
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by Gates Foundation created evidence. Then, we
worked together to develop the guidelines using their
evidence.
Jun Kobayashi So for STH also, there is a planning for
making this kind of evidence?
Kazuyo Ichimori The STH have to do the similar way.
As integrated operation, we are giving the drugs
together in one package, but I think all diseases are
different in epidemiology and biology, so therefore
each disease has to have clear guidelines.
Jun Kobayashi Thank you very much. Very clear.
Fig. 8 Global strategy
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